Melflufen: post-hoc subgroup analyses and the US FDA Oncologic Drugs Advisory Committee-Reference-Cited by-同舟云学术

Melflufen: post-hoc subgroup analyses and the US FDA Oncologic Drugs Advisory Committee

Published:2023-05 Issue:5 Volume:10 Page:e314-e317
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Cliff Edward R Scheffer,Janakiram Murali,Kesselheim Aaron S

Funder

Arnold Ventures LLC

Publisher

Elsevier BV

Subject

Hematology

Reference10 articles.

1. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma;Richardson;J Clin Oncol,2021

2. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study;Gyawali;BMJ,2021

3. Melflufen for multiple myeloma: a promise unfulfilled?;Kapoor;Lancet Haematol,2022

4. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study;Schjesvold;Lancet Haematol,2022

5. Subgroup analysis and other (mis)uses of baseline data in clinical trials;Assmann;Lancet,2000

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review;JNCI Cancer Spectrum;2023-10-31

2. Ensuring Ethical Postprogression Therapy for Patients in Randomized Trial Control Arms;Journal of Clinical Oncology;2023-08-20

3. Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives;Critical Reviews in Oncology/Hematology;2023-07